128 related articles for article (PubMed ID: 38772617)
1.
Cordier F; Creytens D
J Clin Pathol; 2024 Jun; 77(7):435-438. PubMed ID: 38772617
[No Abstract] [Full Text] [Related]
2. The
Berry JL; Polski A; Cavenee WK; Dryja TP; Murphree AL; Gallie BL
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31683923
[TBL] [Abstract][Full Text] [Related]
3. Acral fibromyxoma with loss of Rb1 by immunohistochemistry and fluorescence in situ hybridization: A diagnostically exploitable marker.
Motanagh S; Bridge JA; Linos K
J Cutan Pathol; 2021 Feb; 48(2):295-301. PubMed ID: 32524651
[TBL] [Abstract][Full Text] [Related]
4. Superficial acral fibromyxoma: clinicopathological, immunohistochemical, and molecular study of 11 cases highlighting frequent Rb1 loss/deletions.
Agaimy A; Michal M; Giedl J; Hadravsky L; Michal M
Hum Pathol; 2017 Feb; 60():192-198. PubMed ID: 27825811
[TBL] [Abstract][Full Text] [Related]
5. RB1: a prototype tumor suppressor and an enigma.
Dyson NJ
Genes Dev; 2016 Jul; 30(13):1492-502. PubMed ID: 27401552
[TBL] [Abstract][Full Text] [Related]
6. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
Knudsen ES; Pruitt SC; Hershberger PA; Witkiewicz AK; Goodrich DW
Trends Cancer; 2019 May; 5(5):308-324. PubMed ID: 31174843
[TBL] [Abstract][Full Text] [Related]
7. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
8. Novel insights into RB1 mutation.
Yao Y; Gu X; Xu X; Ge S; Jia R
Cancer Lett; 2022 Oct; 547():215870. PubMed ID: 35964818
[TBL] [Abstract][Full Text] [Related]
9. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
10. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
11. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Beck TN; Georgopoulos R; Shagisultanova EI; Sarcu D; Handorf EA; Dubyk C; Lango MN; Ridge JA; Astsaturov I; Serebriiskii IG; Burtness BA; Mehra R; Golemis EA
Mol Cancer Ther; 2016 Oct; 15(10):2486-2497. PubMed ID: 27507850
[TBL] [Abstract][Full Text] [Related]
12. Translating RB1 predictive value in clinical cancer therapy: Are we there yet?
Indovina P; Pentimalli F; Conti D; Giordano A
Biochem Pharmacol; 2019 Aug; 166():323-334. PubMed ID: 31176618
[TBL] [Abstract][Full Text] [Related]
13. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
14. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
15. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
16. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
[TBL] [Abstract][Full Text] [Related]
17. RB1 5́UTR contains an IRES related to cell cycle control and cancer progression.
Ma W; Ma B; Ma J; Zhu R
Gene; 2023 Dec; 887():147724. PubMed ID: 37604323
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
[TBL] [Abstract][Full Text] [Related]
19. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer molecular analysis of the RB tumor suppressor pathway.
Knudsen ES; Nambiar R; Rosario SR; Smiraglia DJ; Goodrich DW; Witkiewicz AK
Commun Biol; 2020 Apr; 3(1):158. PubMed ID: 32242058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
